Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538-Reference-Cited by-同舟云学术

Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538

Published:2021-01-01 Issue:1 Volume:10 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Klein Oliver¹²,Senko Clare¹,Carlino Matteo S³,Markman Ben⁴⁵,Jackett Louise⁶,Gao Bo³,Lum Caroline⁷,Kee Damien¹⁸,Behren Andreas²⁹,Palmer Jodie²⁹,Cebon Jonathan¹²⁹

Affiliation:

1. Department of Medical Oncology, Austin Health, Melbourne, Australia

2. Olivia Newton-John Cancer Research Institute, Melbourne, Australia

3. Blacktown Hospital and the University of Sydney, Sydney, Australia

4. Department of Medical Oncology, Alfred Health, Melbourne Australia

5. School of Clinical Sciences, Monash University, Melbourne, Australia

6. Department of Anatomical Pathology, Austin Health, Melbourne Australia

7. Department of Medical Oncology, Monash Health, Melbourne, Australia

8. Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

9. School of Cancer Medicine, La Trobe University, Australia

Funder

grant from the Commonwealth of Australia, Dept. Health Accelerated Research Program

Bristol-Myers Squibb

Commonwealth of Australia, Dept. Health Accelerated Research Program

Victorian Cancer Agency

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2021.1908771

Reference29 articles.

1. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study

2. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

3. Combination Chemotherapy in Advanced Adrenocortical Carcinoma

4. Next-generation therapies for adrenocortical carcinoma

5. Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic Management of Advanced Adrenocortical Carcinoma;Current Treatment Options in Oncology;2024-07-27

2. Case report: Ipilimumab and nivolumab in metastatic adrenocortical cancer with high tumor mutational burden;Frontiers in Oncology;2024-06-10

3. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG);Clinical Genitourinary Cancer;2024-06

4. A gut microbial signature for combination immune checkpoint blockade across cancer types;Nature Medicine;2024-03

5. Expression and Prognostic Relevance of PD-1, PD-L1, and CTLA-4 Immune Checkpoints in Adrenocortical Carcinoma;The Journal of Clinical Endocrinology & Metabolism;2024-02-28